## Contents

### REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>517</td>
<td>Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development</td>
<td>Ronan J. Kelly, Elad Sharon, Ira Pastan, and Raffit Hassan</td>
</tr>
<tr>
<td>526</td>
<td>Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm</td>
<td>Sumanta Kumar Pal, Stephen Williams, David Y. Josephson, Courtney Carmichael, Nicholas J. Vogelzang, and David I. Quinn</td>
</tr>
<tr>
<td>538</td>
<td>The Ubiquitin-Proteasome System Meets Angiogenesis</td>
<td>Nader Rahimi</td>
</tr>
</tbody>
</table>

### THERAPEUTIC DISCOVERY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>549</td>
<td>The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo</td>
<td>Kiyohito Kato, Jian Gong, Hisakazu Iwama, Akira Kitakata, Joji Tani, Hisaaki Miyoshi, Kei Nomura, Shima Mimura, Mitsuoshiki Kobayashi, Yuuchi Aritomo, Hideyuki Kobara, Hirohito Mori, Takashi Himoto, Keichi Okano, Yasuyuki Suzuki, Koji Murao, and Tsutomu Masaki</td>
</tr>
<tr>
<td>561</td>
<td>Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Etoposide</td>
<td>Min-Shao Tsai, Shao-Hsing Weng, Huang-Jen Chen, Yu-Fan Chiu, Yu-Ching Huang, Sheng-Chieh Tseng, Ya-Hsun Kuo, and Yun-Wei Lin</td>
</tr>
<tr>
<td>572</td>
<td>Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-κB–Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoinmunotherapeutic Drugs</td>
<td>Melisa A. Martinez-Paniagua, Mario I. Vega, Sara Huerta-Yepez, Stavroula Baritaki, Gabriel G. Vega, Kandasamy Hariharan, and Benjamin Bonavida</td>
</tr>
<tr>
<td>582</td>
<td>Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3</td>
<td>Charlotte F. McDonagh, Alexandrea Huhalov, Brian D. Harms, Sharlene Adams, Violette Paragas, Shinji Oyama, Bo Zhang, Lia Luus, Ryan Overland, Stephanie Nguyen, Jimming Gu, Neeraj Kohli, Matt Wallace, Michael J. Feldhaus, Arthur J. Kudla, Birgit Schoebel, and Ulrik B. Nielsen</td>
</tr>
<tr>
<td>594</td>
<td>A Human Fab-Based Immunoconjugate Specific for the LMP1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo</td>
<td>Renjie Chen, Dawei Zhang, Yuan Mao, Jin Zhu, Hao Ming, Juan Wen, Jun Ma, Qing Cao, Hong Lin, Qi Tang, Jie Liang, and Zhengqin Feng</td>
</tr>
<tr>
<td>629</td>
<td>Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer</td>
<td>Peter M. Wilson, Melissa J. LaBonte, Heinz-Josef Lenz, Philip C. Mack, and Robert D. Ladner</td>
</tr>
<tr>
<td>639</td>
<td>DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma</td>
<td>Xiao Xu, Rui-Fang Liu, Xin Zhang, Li-Yu Huang, Fei Chen, Qian-Lan Fei, and Ze-Guang Han</td>
</tr>
</tbody>
</table>

### Molecular Cancer Therapeutics

**The Cancer Drug Development Journal: From Concept to Clinic**

March 2012 • Volume 11 • Number 3

Contents

Highlights of This Issue 515

REVIEWS

517  | Mesothelin-Targeted Agents in Clinical Trials and in Preclinical Development | Ronan J. Kelly, Elad Sharon, Ira Pastan, and Raffit Hassan |
526  | Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm | Sumanta Kumar Pal, Stephen Williams, David Y. Josephson, Courtney Carmichael, Nicholas J. Vogelzang, and David I. Quinn |
538  | The Ubiquitin-Proteasome System Meets Angiogenesis | Nader Rahimi |

THERAPEUTIC DISCOVERY

549  | The Antidiabetic Drug Metformin Inhibits Gastric Cancer Cell Proliferation In Vitro and In Vivo | Kiyohito Kato, Jian Gong, Hisakazu Iwama, Akira Kitakata, Joji Tani, Hisaaki Miyoshi, Kei Nomura, Shima Mimura, Mitsuoshiki Kobayashi, Yuuchi Aritomo, Hideyuki Kobara, Hirohito Mori, Takashi Himoto, Keichi Okano, Yasuyuki Suzuki, Koji Murao, and Tsutomu Masaki |
561  | Inhibition of p38 MAPK-Dependent Excision Repair Cross-Complementing 1 Expression Decreases the DNA Repair Capacity to Etoposide | Min-Shao Tsai, Shao-Hsing Weng, Huang-Jen Chen, Yu-Fan Chiu, Yu-Ching Huang, Sheng-Chieh Tseng, Ya-Hsun Kuo, and Yun-Wei Lin |
572  | Galiximab Signals B-NHL Cells and Inhibits the Activities of NF-κB–Induced YY1- and Snail-Resistant Factors: Mechanism of Sensitization to Apoptosis by Chemoinmunotherapeutic Drugs | Melisa A. Martinez-Paniagua, Mario I. Vega, Sara Huerta-Yepez, Stavroula Baritaki, Gabriel G. Vega, Kandasamy Hariharan, and Benjamin Bonavida |
582  | Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3 | Charlotte F. McDonagh, Alexandrea Huhalov, Brian D. Harms, Sharlene Adams, Violette Paragas, Shinji Oyama, Bo Zhang, Lia Luus, Ryan Overland, Stephanie Nguyen, Jimming Gu, Neeraj Kohli, Matt Wallace, Michael J. Feldhaus, Arthur J. Kudla, Birgit Schoebel, and Ulrik B. Nielsen |
594  | A Human Fab-Based Immunoconjugate Specific for the LMP1 Extracellular Domain Inhibits Nasopharyngeal Carcinoma Growth In Vitro and In Vivo | Renjie Chen, Dawei Zhang, Yuan Mao, Jin Zhu, Hao Ming, Juan Wen, Jun Ma, Qing Cao, Hong Lin, Qi Tang, Jie Liang, and Zhengqin Feng |
629  | Inhibition of dUTPase Induces Synthetic Lethality with Thymidylate Synthase–Targeted Therapies in Non–Small Cell Lung Cancer | Peter M. Wilson, Melissa J. LaBonte, Heinz-Josef Lenz, Philip C. Mack, and Robert D. Ladner |
639  | DLK1 as a Potential Target against Cancer Stem/Progenitor Cells of Hepatocellular Carcinoma | Xiao Xu, Rui-Fang Liu, Xin Zhang, Li-Yu Huang, Fei Chen, Qian-Lan Fei, and Ze-Guang Han |

212Pb-Radioimmunotherapy Induces G2 Cell-Cycle Arrest and Delays DNA Damage Repair in Tumor Xenografts in a Model for Disseminated Intraperitoneal Disease

Kwon Joong Yong, Diane E. Milenic, Kwamena E. Baidoo, and Martin W. Brechbiel
An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735
Kenneth E. Hook, Scott J. Garza, Maruja E. Lira, Keith A. Ching, Nathan V. Lee, Joan Cao, Jing Yuan, Jingjing Ye, Mark Ozeck, Stephanie T. Shi, Xianxian Zheng, Paul A. Rejto, Julie L.C. Kan, James G. Christensen, and Adam Pavlicek

Comprehensive Predictive Biomarker Analysis for MEK Inhibitor GSK1120212
Junping Jing, Joel Greshock, Joanna Dawn Holbrook, Aidan Gilmartin, Xiping Zhang, Elizabeth McNeil, Theresa Conway, Christopher Moy, Sylvie Laquerre, Kurt Bachman, Richard Wooster, and Yan Degenhartd

The Novel Oral Hsp90 Inhibitor NVP-HSP990 Exhibits Potent and Broad-spectrum Antitumor Activities In Vitro and In Vivo

Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Fanying Meng, James W. Evans, Deepthi Bhupathi, Monica Banica, Leslie Lan, Gustavo Lorente, Jian-Xin Duan, Xiaohong Cai, Alexandra M. Mogrady, Christopher P. Guise, Andrej Maroz, Robert F. Anderson, Adam V. Patterson, Gregory C. Stachelek, Peter M. Glazer, Mark D. Matteucci, and Charles P. Hart

Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration in a Preclinical Breast Cancer Model
Cinthia V. Pastuskovas, Eduardo E. Mundo, Simon P. Williams, Tapan K. Nayak, Jason Ho, Sheila Ulufatu, Suzanna Clark, Sarajane Ross, Eric Cheng, Kathryn Parsons-Reporto, Gary Cain, Marie Van Hoy, Nicholas Majidy, Sheila Bheddah, Josefa dela Cruz Chuh, Katherine R. Kozak, Nicholas Lewin-Koh, Peter Nauka, Daniela Bumbaca, Frank-Peter Theil, Paul J. Fielder, Leslie A. Khawil, and C. Andrew Boswell
The Aurora Kinase A Inhibitor MLN8237 Enhances Cisplatin-Induced Cell Death in Esophageal Adenocarcinoma Cells
Vikas Sehdev, DunFa Peng, Mohammed Souito, M. Kay Washington, Frank Revetta, Jeffrey Ecsedy, Alexander Zaika, Tilman T. Rau, Regine Schneider-Stock, Abbes Belkhiri, and Wael El-Rifai

MOLECULAR MEDICINE IN PRACTICE

Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target

ABOUT THE COVER

The uracil-metabolizing enzyme dUTPase is a key component of de novo thymidine nucleotide biosynthesis and its expression is tightly regulated in replicating tissues such as the follicular germinal centers of human palatine tonsil (pictured). However, dUTPase is frequently overexpressed in human cancers and this has been firmly linked to drug resistance to chemotherapeutic agents that target thymidylate synthase (TS). Using immunohistochemistry and quantitative RT-PCR, evidence of dUTPase overexpression in a cohort of non-small cell lung cancers (NSCLC) was observed. Small interfering RNA-mediated gene silencing of dUTPase induced a strong synthetic lethal effect in NSCLC cell lines to two class-specific TS-targeted therapies including pemetrexed and fluorodeoxyuridine. Inhibition of dUTPase represents a promising, mechanism-based therapeutic approach to significantly enhance the efficacy of TS-targeted chemotherapeutic agents by overcoming a critical drug resistance pathway. For details, see article by Wilson and colleagues on page 616.
Molecular Cancer Therapeutics

11 (3)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/3

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.